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1. Introduction
1.1. Review of the relationship between n-3 polyunsaturated fatty acids and the atrial
fibrillation
It is well established that the consumption of fish is associated with lower rates of cardiovas‐
cular death (Albert CM,et al.,2002; Hu FB, et al.,2002). Dietary fish oil supplementation has
been shown to reduce mortality in high-risk groups through a reduction in sudden cardiac
death and ventricular tachyarrhythmia. It has been recently reported that atrial fibrillation
(AF) is associated with inflammation and inflammatory cytokines, and n-3 polyunsaturated
fatty acids (PUFAs) might be of anti-inflammatory effects. Whether PUFAs has some antiar‐
rhythmic effect and can be used in the treatment of AF is still unknown.
1.2. Dietary n-3 PUFA supplementation attenuates the inducibility and maintenance of
AF
We established canine sterile pericarditis model and evaluate the anti-inflammatory effect of
PUFAs on AF(Zhong Zhang,et al.,2010). Twenty mongrel sex-matched adult dogs were ran‐
domly divided into two groups. In the n-3 PUFA group (n=10), oral administration ofeicosa‐
pentaenoic+docosahexaenoic acid (EPA+DHA), 2 g/day (Omacor, Solvay Pharmaceuticals
GmbH, Hanover, Germany) was started 4 weeks before the baseline study, and was contin‐
ued until the end of the study. The dogs in the control group (n=10) did not receive n-3 PU‐
FAs or plant oil for 4 weeks. We examined the plasma concentration of the CRP, IL-6, and
© 2013 Zheng et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
TNF-α before the operation and on the second postoperative day in both groups. There were
no significant differences in three biomarkers of inflammation between two groups before
the operation, and these biomarkers were significantly increased in both groups on the sec‐
ond postoperative day. However, three proinflammatory cytokines were significantly lower
in the PUFA group than in the control group respectively (CRP, 7.6±0.5 vs. 11.7± 1.3 mg/dl,
Pb0.0001 Fig. 1; IL-6, 112.0±37.3 vs. 142.0±19.6 pg/ml, Pb0.0001 Fig. 2; TNF-α, 83.3±8.5 vs.
112.4±8.2 pg/ml, Pb0.0001 Fig. 3).
Figure 1. Comparison of CRP levels between the control and PUFA groups before and after operation. Before the op‐
eration, there were no significant differences in CRP levels between two groups. On the second postoperative day,
CRP was significantly increased in both groups; however, it was significantly lower in the PUFA group than in the con‐
trol.
The main finding of this study is that EPA and DHA supplementation of the diet can de‐
crease plasma concentration of the CRP, IL-6 and TNF-α in acute inflammation of canine
sterile pericarditis, suggesting depression of inflammatory cytokines by n-3 FUFAs may in‐
volve in the anti-atrial fibrillation process. The results also showed that the PUFA group had
a less AF inducibility and maintenance than the control group (Table1).
Thus we may reasonably conclude that Dietary n-3 PUFA supplementation attenuates the
inducibility and maintenance of AF in the sterile pericarditis model by reducing the produc‐
tion of proinflammatory cytokines.
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Figure 2. Comparison of IL-6 levels between the control and PUFA groups before and after operation. Before opera‐
tion, there were no significant differences in IL-6 levels between two groups. On the second postoperative day, IL-6
was significantly increased in both groups; however, it was significantly lower in the PUFA group than in the control.
Figure 3. Comparison of TNF-α levels between the control and PUFA groups before and after operation. Before the
operation, there were no significant differences in TNF- α levels between two groups. On the second postoperative
day, TNF- α was significantly increased in both groups; however, it was significantly lower in PUFA group than in the
control.
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CT=conduction time; RAA=right atrial appendage; LRA=low lateral right atrium; HRA=high lateral right atrium; ARA=
anterior right atrium.
†p<0.05 compared with before the operation
# p<0.0001 compared with before the operation
* P<0.05 compared with the control group
‡ p<0.01 compared with before operation.
Table 1. Comparison of electrophysiological parameters (CT) between the control and PUFA groups before and after
operation
1.3. Inflammation and post cardiac surgery AF
Although the pathophysiological mechanism underlying the genesis of post cardiac surgery
AF has been the focus of many studies,it only remains partially understood. The inflamma‐
tory cascade and catecholamine surge associated with surgery have been thought of playing
a prominent role in initiating AF after cardiac surgery. As a prototypic marker of inflamma‐
tion, CRP has been the focus of many studies, which is driven by the proinflammatory cyto‐
kines interleukin (IL)-1, tumor necrosis factor (TNF)-α, and IL-6(Bruins P et al.,1997) found
that IL-6 rises initially and peaks at 6 h after cardiac surgery, and CRP levels increases and
peaks on the second postoperative day of the cardiac surgery, with complement-CRP com‐
plexes levels peaking on the 2nd or 3rd postoperative day. The incidence of atrial arrhyth‐
mias similarly peaks on postoperative day 2 or 3. Other researchers have confirmed that IL-6
and CRP increased after cardiac surgery, with the incidence of atrial arrhythmias similarly
peaking on the 2nd or 3rd postoperative day [13,14](Ishida K,et al.,2006;Kumagai K,et al.,
2004). Many studies have related an increase in CRP and IL-6 in both paroxysmal AF and
persistent AF, and concluded that CRP is not only associated with the presence of AF but
may also predict an increased risk for future development of AF [15](Aviles RJ,et al.,2003).
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Other studies correlated leukocytosis to an increased incidence in AF in postoperative cardi‐
ovascular patients [16,17](Abdelhadi RH,et al.,2004;Lamm G,et al.,2006), and found that a
more pronounced increase in postoperative WBC count will independently predict develop‐
ment of postoperative AF. Moreover, atrial inflammation of cardiac surgery effects on the
electrical properties of atrial tissue, and the degree of atrial inflammation was associated
with a proportional increase in the inhomogeneity of atrial conduction and AF duration [18]
( Ishii Y, et al.,2005). Administration of anti-inflammatory drugs (dexamethasone or corti‐
sone) significantly decreases the incidence of AF after cardiac surgery [19,20](Yred JP,et al.,
2000;Halonen J,et al.,2007), which supports this inflammation-AF
hypothesis. The canine sterile pericarditis model can perfectly simulate inflammatory cir‐
cumstances of the post cardiac operation, by which AF can be induced and also peaks on the
2nd postoperative day [10](Page PL,et al.,1986). In this model, the multiple unstable reen‐
trant circuits were showed during AF, and it was critical for maintaining AF [10] (Page PL,et
al.,1986). According to the multiple-wavelet hypothesis, atrial wavelength determines the
number of wavelets, and the atrial wavelength is the product of AERP and the intra-atrial
conduction velocity. So, the AERP and the intra-atrial conduction velocity have been
thought to be important for the perpetuation of AF. In this canine sterile pericarditis model,
we have evaluated CRP, IL-6 and TNF-α level on the baseline and on the 2nd postoperative
day, and found that they all significantly increased in both groups. We simultaneously eval‐
uated the role of inflammation on atrial electrophysiological properties, and found that in‐
flammation can shorten AERPs and prolong intra-atrial CT in the canine sterile pericarditis
model, which increased the inducibility and stability of AF. Our results are concordant with
the previous results. Thus, in this model, elevated CRP, IL-6 and TNF-α were associated
with sustained AF, suggesting that electrophysiological changes resulting from inflamma‐
tion perpetuate AF.
1.4. Other potential mechanisms of antiarrhythmic action of n-3 PUFA administration
The current hypotheses of n-3 PUFAs in preventing AF are based on their inhibiting ca‐
pacity  of  some ion channels.  Previous  studies  have demonstrated that  n-3  PUFAs have
capacity to inhibit  fast,  voltage dependent sodium currents,  L-type calcium currents,  the
Na /Ca2 exchanger, which might prevent delayed after-depolarizations and triggered ac‐
tivity, as well as their class III antiarrhythmic-like effect on Kv1.5 channel (IKUR current
present  in  the  atrium)  [36,37](Xial  YF,et  al.,2004;Honore  E,et  al.,1994).  Other  studies
found n-3 PUFAs can attenuate atrial structural remodeling not only by activating matrix
metalloproteinase-9 mRNA expression and attenuating of collagen turnover [38](Laurent
G,et al.,2008), but also by modulating of atrial gap junction protein CX40 and CX43 [39]
(Sarrazin JF,et al.,2007). Otherwise, evidence suggests that n-3 fatty acids consumption at‐
tenuates  oxidative  stress  in  humans,  and the  underlying mechanisms may lead to  sup‐
pressed  production  of  reactive  oxygen  species  by  leukocytes,  inhibition  of  the  pro-
oxidant  enzyme  phospholipase  A2,  and  induction  of  antioxidant  enzymes  [40](Mori
TA,et al.,2003).
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2. The expression of CD69 and CD3+ T-lymphocytes in the diagnosis or
therapy of AF
Recently,  the  link  between  inflammation  and  AF  appeals  increasing  attention.  Many
studies  have demonstrated serum or  plasma inflammation biomarkers  have a  link with
the development of  AF,  which supported chronic inflammatory responses might partici‐
pate in the development of AF (Chung MK et al.,2006;Hemandez Madrid A et al.,2007;Li
J et al.,2010;Psychari SN et al.,2005).  Moreover, some other studies reported that activat‐
ed T-lymphocytes and macrophages infiltrated the endomyocardial  of  patients  with AF,
which supported the activation of local T-lymphocytes played a role in the pathogenesis
of  AF (Chen MC et  al.,  2008;Nakamura Y et  al.,2003;Yamashita T et  al.,2010).  However,
up to now, there are no evidences supporting the link between the activation of periph‐
eral blood T-lymphocytes and AF. As is well-known, CD69 and HLA-DR are markers of
activated T-lymphocytes. In other words, they are both specifically expressed on the sur‐
face of  activated T-lymphocytes.[11,  12](Caruso A et  al.,1997;Reddy M et  al.,2004)  CD69
is known as an early activation marker of T-lymphocytes [13](Sancho D et  al.,2005) and
HLA-DR is  known as  a  late  activation marker  of  T-lymphocytes.[14]  (Geraldes  L  et  al.,
2010)They both play a role in the specific immune response to inflammation. [15, 16,  14,
17-19, 13, 20] (Sancho D et al.,2005;Geraldes L et al.,2010;Afeltra A et al.,1993;Ferenczi K
et  al.,2000;McDonald  GB  et  al.,1987;Miki-Hosokawa  T  et  al.,2009;Oczenski  W  et  al.,
2003;Vance BA et  al.,2005)  To our knowledge,  there is  little  information available  about
the  expression  of  CD69  and  HLA-DR  on  peripheral  blood  CD3+  T-lymphocytes  in  pa‐
tients  with AF.Thus we designed an experiment  to  investigate  the relationship between
the activation of peripheral blood CD3+ T-lymphocytes and AF by flow cytometric analy‐
sis that we aimed to provide more evidences to support this phenomenon (Liu L, et al.,
2012;53(4):221-4.)
Fifty paroxysmal AF patients and fifty-six persistent AF patients, underwent successful elec‐
trical cardioversion, were enrolled in this study. Percentage of CD69 and Human leukocyte
antigen DR (HLA-DR) positive peripheral blood CD3+ T-lymphocyte, which indicates T-
lymphocyte activation, were examined by flow cytometric analysis in the patients and fifty-
one healthy controls. Patients groups had higher levels of CD69 and HLA-DR than healthy
controls. During three-month follow-up, 37 patients had recurrence of AF (recurrence
group) and 50 patients remained in sinus (sinus group).
The results showed that Patients with AF groups had higher levels of CD69 and HLA-DR
than healthy controls. The mean value of CD69 was significantly up-regulated in patients
with paroxysmal (1.48%±0.42) and persistent AF (1.55%±0.38) compared with healthy indi‐
viduals (1.07%±0.37; all p<0.001). The mean value of HLA-DR was also significantly up-
regulated in patients with paroxysmal (35.16%±10.89) and persistent AF (37.73%±10.78)
compared with healthy individuals (26.6%±8.41; all p<0.001. Figure 4)
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Figure 4. Percentage of CD3+CD69+ T-lymphocytes (A) and CD3+HLA-DR+ T-lymphocytes (B) were shown, respectively.
During three-month follow-up, 37 patients had recurrence of AF (recurrence group) and 50
patients remained in sinus (sinus group). The results demonstrated that the mean values of
CD69 and HLA-DR in sinus group at follow-up (1.17%±0.38, 28.71%±8.70) were all signifi‐
cantly down-regulated compared with before cardioversion (1.45%±0.44, 34.71%±9.75; all
p<0.05). However, there were no statistically significant differences between recurrence
group at follow-up (1.57%±0.39, 36.40%±9.32) and before cardioversion (1.60%±0.35, 37.72%
±11.11; p=0.721, p=0.544. Figure.5)
Figure 5. The mean values of CD3+CD69+ T-lymphocytes (A) and CD3+HLA-DR+ T-lymphocytes (B) in the sinus group
and recurrence group at follow-up and before cardioversion.
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Before we received the result,we conduct the baseline clinical Caracteristics of the Studied
Population to ensure facticity of the results (Table 2).
Control
(n=51)
Paroxysmal AF (n=50) Persistent AF (n=56) p
Age(yrs) 64.4±8.5 64.3±9.5 67.2±9.7 0.176
Men 31 (61%) 32 (64%) 34 (61%) 0.927
Hypertension 13 (25%) 20 (40%) 25 (45%) 0.106
Hyperlipidemia 11 (22%) 8 (16%) 7 (13%) 0.448
Diabetes 2 (4%) 3 (6%) 5 (9%) 0.566
Drugs:
ACE-I/ARB 10 (20%) 11 (22%) 21 (38%) 0.074
Statins 8 (16%) 7 (14%) 6 (11%) 0.743
β-blockers 8 (16%) 26 (52%) 30 (54%) <0.001
CCBs 5 (10%) 12 (24%) 7 (13%) 0.108
WBC count(per uL) 6349±1891 6768±1859 6375±1663 0.819
Lymphocytes(%) 30.9±3.8 32.5±4.3 31.5±4.1 0.147
Monocytes(%) 5.5±1.2 5.8±1.1 5.4±1.1 0.123
CRP(mg/dl) 0.24±0.12 0.48±0.25 0.60±0.22* <0.001
Table 2. Caracteristics of the Studied Population
ACEI indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor block‐
ing agents; CCBs, calcium channel blockers; WBC, white blood cells; CRP, C-reactive pro‐
tein; p, probability of significance (difference among three groups); and *, p<0.05 persistent
AF vs paroxysmal AF.
In this study, we found that the respective expression of CD69 and HLA-DR on peripheral
blood CD3+ T-lymphocytes in AF patients was significantly higher than control group,
which might suggest that high expression of CD69 and HLA-DR was associated with AF. In
the subsequent follow-up, we further found that the expression of CD69 and HLA-DR in si‐
nus group at follow-up was significantly down-regulated compared with before cardiover‐
sion. However, the expression of CD69 and HLA-DR in recurrence group at follow-up was
not significantly down-regulated. It might further support that the CD69 and HLA-DR lev‐
els were related with the state of AF.
As demonstrated by the present study, there was a link between high expression of CD69
and HLA-DR and AF. CD69, known as an early activation marker of lymphocytes, is a type
II transmembrane glucoprotein and may enhance activation and proliferation/differentiation
of T-lymphocytes. (Sancho D et al. 2005;Vance BA et al.,2005;Beeler A et al.,2008;Creeners P
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et al.,2002) HLA-DR belongs to the MHC class II system which is known as a late activation
marker of lymphocytes. It is required for antigen presentation and activation of helper T-
lymphocytes. (Geraldes L et al.,2010;Oczenski W et al.,2003;Bobryshev YV et al.,2011)They
respectively expressed in some inflammatory infiltrates and played important roles in the
pathogenesis of some inflammatory diseases such as allergic airway inflammation, (Miki-
Hosokawa T et al.,2009;Wang HY et al.,2006) rheumatoid arthritis, (Afeltra A et al.,1993)
psoriasis vulgaris lesional skin active inflammatory bowel disease (McDonald GB et al.,
1987). So the increase of CD69 and HLA-DR on CD3+ T-lymphocytes implied there is an acti‐
vation of peripheral blood CD3+ T-lymphocytes in AF patients.
In fact, the activation of peripheral blood CD3+ T-lymphocytes maybe plays an important
role in the pathogenesis of AF. A few studies reported that some inflammatory lympho‐
cytes, such as CD45+ cells, CD3+ T cells, and CD68+ macrophages, infiltrated in the endomyo‐
cardial in patients with AF, which supported the local activation of T-lymphocytes played a
role in the pathogenesis of AF.(Chen MC et al.,2008;Nakamura Y et al.,2003;Yamashita T et
al.,2010) On the other hand, a lot of studies reported that serum or plasma inflammation bio‐
markers, such as C-reactive protein (CRP), interleukin (IL)-6, IL-8, IL-10, tumor necrosis fac‐
tor (TNF)-α, monocyte chemotactic protein (MCP)-1, vascular endothelial growth factor
(VEGF), et al., increased in AF patients, which supported T-cell-associated chronic inflam‐
matory responses might involve in the pathogenesis of AF. (Chung MK et al.,2001;Heman‐
dez Madrid A et al.,2007;Li J et al.,2010;Psychari SN et al.,2005) In our study, we provided
another evidence to support that there is an activation of peripheral blood CD3+ T-lympho‐
cytes in AF patients, demonstrated by the upregulation of CD69 and HLA-DR by flow cyto‐
metric analysis.
Generally, our study here further emphasize that activation of T cells is involved in AF. As
we all know, T-lymphocytes are the main cells participate in cell-mediated immunity, which
is one of the primary ways of human immune. It can be suppressed by many immunosup‐
pressants such as Cyclosporine, Rapamycin, et al. If the activation of peripheral blood T-
lymphocytes does participate in the pathogenesis of AF, maybe we can prevent recurrence
of AF through suppressing the activation of peripheral blood T-lymphocytes.
As for the underlying mechanisms of activated peripheral blood CD3+ T-lymphocytes partic‐
ipates in the progression of AF, we speculate the following three possibilities. Firstly, the ac‐
tivation of peripheral blood CD3+ T-lymphocytes might cause the upregulation of IL-6 and
MCP-1, which could affect the contractility and electrical stability of myocytes inhomogene‐
ously and induce fibroblast activation leading to deposits of extracellular matrix fibrosis.
(Ramos-Mondragon R et al.,2008) Secondly, activation of peripheral blood CD3+ T-lympho‐
cytes might promote the local immunologic inflammatory responses in the endomyocardial,
and promote infiltrate of inflammatory lymphomononuclear in the endomyocardial in pa‐
tients with AF. Thirdly, the activation of peripheral blood CD3+ T-lymphocytes could acti‐
vate the calcineurin-nuclear factor, which involve in the T-lymphocytes signal transduction
pathway. (Lin CC et al., 2004)
It is important to note that there are several limitations that need to be addressed regarding
this study. Firstly, The results cannot be taken as evidence to support that CD69 and HLA-
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DR play a role in the pathogenesis of AF, it only indicate the possible association of CD69
and HLA-DR with AF. Secondly, how CD69 and HLA-DR contribute to the pathogenesis of
AF and what is the underlying mechanism need to be further investigated. Thirdly, we did
not study the influence of other immune activation-associated molecules (CD25, CD71, and
CD122, et al) and co-stimulatory molecules (CD28, CTLA-4, CD80, CD86, et al) during the
progression of AF.
3. Summary
The activation of  peripheral  blood CD3+ T-lymphocytes and immunologic inflammatory
responses played a role in the pathogenesis of AF,and might be a diagnostic or therapeu‐
tic  marker.  Dietary  n-3  PUFA  supplementation  attenuates  the  inducibility  and  mainte‐
nance  of  AF  in  the  sterile  pericarditis  model  by  reducing  the  production  of
proinflammatory cytokines.
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